Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 47Neoplasm Metastasis 9Neoplasms 8Prostatic Neoplasms 7Brain Neoplasms 7Endometrial Neoplasms 6Glioblastoma 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Meningioma 3Carcinoma, Renal Cell 3Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Liposarcoma 2Hematologic Neoplasms 2Glioma 2Breast Neoplasms, Male 2Breast Diseases 2Breast Cancer Female 2Venous Thromboembolism 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1

Interventions

evening primrose oil 1abemaciclib 1Tamoxifen 1Mammography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fibrocystic Breast Disease × abemaciclib × Clear all
NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡